Steve L. McAfee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steve L. McAfee has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aj S. Bottoms
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
29 shared publications - Alice S. Mims
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
29 shared publications - Amir Tahmasb Fathi
Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States
29 shared publications - Andrew Mark Brunner
Center for Leukemia, Massachusetts General Hospital, Boston, MA, USA
29 shared publications - Annette S. Kim
University of Michigan
29 shared publications - Areej El-Jawahri
Massachusetts General Hospital, Boston, MA
29 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants